Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacometrics Can Guide Further Trials, Minimize Risks – FDA Analysis

Executive Summary

Pharmacometric analysis can be used to refine the design of further studies following failed clinical trials, according to an analysis by reviewers in FDA's Office of Clinical Pharmacology & Biopharmaceutics

You may also be interested in...



What Not To Do: FDA Reviewer Talks Cancer Drug Development Mistakes

Using anonymous examples at the recent AACR meeting, FDA’s Tatiana Prowell highlights mistakes made and lessons learned in oncology drug reviews.

Can FDA Learn From Industry’s Risk/Benefit Decisions?

FDA is seeking insight into the pharmaceutical industry's pipeline management decisions as it works to improve its own risk/benefit analyses

Can FDA Learn From Industry’s Risk/Benefit Decisions?

FDA is seeking insight into the pharmaceutical industry's pipeline management decisions as it works to improve its own risk/benefit analyses

Related Content

Topics

UsernamePublicRestriction

Register

PS046390

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel